Synapse-specific contributions in the cortical pathology of schizophrenia

Neurobiology of Disease

Volumn 53, Issue , 2013, Pages 26-35

  Seshadri, Saurav ^a   Zeledon, Mariela ^a   Sawa, Akira ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Connectivity; DISC1; Dysbindin; Genetic factors; Neuregulin 1; Schizophrenia; Synapse

Indexed keywords

DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DYSBINDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLUTAMATE DECARBOXYLASE 67; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR;

4 AMINOBUTYRIC ACID RELEASE; BRAIN CORTEX; BRAIN REGION; DNA POLYMORPHISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; GABAERGIC TRANSMISSION; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HUMAN; INTERNEURON; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SYNAPSE;

ANIMALS; CEREBRAL CORTEX; HUMANS; NERVE NET; NEURONS; PRESYNAPTIC TERMINALS; SCHIZOPHRENIA; SYNAPSES;

EID: 84875262788     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.01.009     Document Type: Review

References (177)

1. Abe Y., et al. Neuregulin-1 signals from the periphery regulate AMPA receptor sensitivity and expression in GABAergic interneurons in developing neocortex. J. Neurosci. 2011, 31:5699-5709.
2. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 2004, 7(Suppl. 1):S1-S5.
3. Abi-Dargham A., Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003, 9:404-416.
4. Abi-Dargham A., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 2002, 22:3708-3719.
5. Akbarian S., et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 1995, 52:258-266.
6. Akil M., et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry 1999, 156:1580-1589.
7. Albert K.A., et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch. Gen. Psychiatry 2002, 59:705-712.
8. Anton E.S., et al. Receptor tyrosine kinase ErbB4 modulates neuroblast migration and placement in the adult forebrain. Nat. Neurosci. 2004, 7:1319-1328.
9. Arnsten A.F. Catecholamine regulation of the prefrontal cortex. J. Psychopharmacol. 1997, 11:151-162.
10. Arnsten A.F. Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia. Int. J. Dev. Neurosci. 2011, 29:215-223.
11. Arnsten A.F., Goldman-Rakic P.S. Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch. Gen. Psychiatry 1998, 55:362-368.
12. Arnsten A.F., et al. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 1994, 116:143-151.
13. Arnsten A.F., et al. The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys. Neuropsychopharmacology 2000, 23:405-410.
14. Asada H., et al. Cleft palate and decreased brain gamma-aminobutyric acid in mice lacking the 67-kDa isoform of glutamic acid decarboxylase. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:6496-6499.
15. Bacon S.J., et al. Amygdala input to medial prefrontal cortex (mPFC) in the rat: a light and electron microscope study. Brain Res. 1996, 720:211-219.
16. Belforte J.E., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat. Neurosci. 2010, 13:76-83.
17. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25:1-27.
18. Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology 2008, 33:2175-2186.
19. Beneyto M., et al. Lamina-specific alterations in cortical GABA(A) receptor subunit expression in schizophrenia. Cereb. Cortex 2011, 21:999-1011.
20. Bergson C., et al. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J. Neurosci. 1995, 15:7821-7836.
21. Black J.E., et al. Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am. J. Psychiatry 2004, 161:742-744.
22. Braff D.L., et al. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry 1992, 49:206-215.
23. Branco T., Hausser M. Synaptic integration gradients in single cortical pyramidal cell dendrites. Neuron 2011, 69:885-892.
24. Brandon N.J., Sawa A. Linking neurodevelopmental and synaptic theories of mental illness through DISC1. Nat. Rev. Neurosci. 2011, 12:707-722.
25. Buchsbaum M.S., et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. 2006, 85:232-244.
26. Cahill M.E., et al. Control of interneuron dendritic growth through NRG1/erbB4-mediated kalirin-7 disinhibition. Mol. Psychiatry 2012, 17(1):99-107.
27. Camargo L.M., et al. Disrupted in schizophrenia 1 interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol. Psychiatry 2007, 12:74-86.
28. Carlen M., et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol. Psychiatry 2011, 17:537-548.
29. Carlson G.C., et al. Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E962-E970.
30. Carlsson T., et al. Systemic administration of neuregulin-1beta1 protects dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurochem. 2011, 117:1066-1074.
31. Chen Y., et al. Intramembranous valine linked to schizophrenia is required for neuregulin 1 regulation of the morphological development of cortical neurons. J. Neurosci. 2010, 30:9199-9208.
32. Conde F., et al. Local circuit neurons immunoreactive for calretinin, calbindin D-28k or parvalbumin in monkey prefrontal cortex: distribution and morphology. J. Comp. Neurol. 1994, 341:95-116.
33. Crook J.M., et al. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol. Psychiatry 2002, 7:157-164.
34. Cropley V.L., et al. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol. Psychiatry 2006, 59:898-907.
35. Davidson L.L., Heinrichs R.W. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a meta-analysis. Psychiatry Res. 2003, 122:69-87.
36. De Gois S., et al. Homeostatic scaling of vesicular glutamate and GABA transporter expression in rat neocortical circuits. J. Neurosci. 2005, 25:7121-7133.
37. Deakin I.H., et al. Behavioural characterization of neuregulin 1 type I overexpressing transgenic mice. Neuroreport 2009, 20:1523-1528.
38. Deakin I.H., et al. Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation. Cereb. Cortex 2012, 22:1520-1529.
39. DeFelipe J. Chandelier cells and epilepsy. Brain 1999, 122(Pt 10):1807-1822.
40. Duncan C.E., et al. Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J. Psychiatr. Res. 2010, 44:673-681.
41. Eastwood S.L., et al. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res. Mol. Brain Res. 1995, 29:211-223.
42. El-Husseini A.E., et al. PSD-95 involvement in maturation of excitatory synapses. Science 2000, 290:1364-1368.
43. Farzan F., et al. Evidence for gamma inhibition deficits in the dorsolateral prefrontal cortex of patients with schizophrenia. Brain 2010, 133:1505-1514.
44. Fazzari P., et al. Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature 2010, 464:1376-1380.
45. Fitzgerald M.L., et al. Altered dendritic distribution of dopamine D2 receptors and reduction in mitochondrial number in parvalbumin-containing interneurons in the medial prefrontal cortex of cannabinoid-1 (CB1) receptor knockout mice. J. Comp. Neurol. 2012, 520:4013-4031.
46. Fleming K., et al. Visuospatial working memory in patients with schizophrenia. Biol. Psychiatry 1997, 41:43-49.
47. Floresco S.B., Tse M.T. Dopaminergic regulation of inhibitory and excitatory transmission in the basolateral amygdala-prefrontal cortical pathway. J. Neurosci. 2007, 27:2045-2057.
48. Freund T.F. Interneuron diversity series: rhythm and mood in perisomatic inhibition. Trends Neurosci. 2003, 26:489-495.
49. Fung S.J., et al. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am. J. Psychiatry 2008, 167:1479-1488.
50. Gabriel S.M., et al. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol. Psychiatry 1996, 39:82-91.
51. Gao W.J., Goldman-Rakic P.S. Selective modulation of excitatory and inhibitory microcircuits by dopamine. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2836-2841.
52. Gao W.J., et al. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:295-300.
53. Gao W.J., et al. Dopamine modulation of perisomatic and peridendritic inhibition in prefrontal cortex. J. Neurosci. 2003, 23:1622-1630.
54. Garey L. When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits. J. Anat. 2010, 217:324-333.
55. Glahn D.C., et al. Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol. Psychiatry 2008, 64:774-781.
56. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 2000, 57:65-73.
57. Glausier J.R., Lewis D.A. Selective pyramidal cell reduction of GABA(A) receptor alpha1 subunit messenger RNA expression in schizophrenia. Neuropsychopharmacology 2011, 36:2103-2110.
58. Gold J.M., et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch. Gen. Psychiatry 1997, 54:159-165.
59. Goldman-Rakic P.S. Cellular basis of working memory. Neuron 1995, 14:477-485.
60. Goldman-Rakic P.S., et al. D(1) receptors in prefrontal cells and circuits. Brain Res. Brain Res. Rev. 2000, 31:295-301.
61. Graziane N.M., et al. Dopamine D4 receptors regulate GABAA receptor trafficking via an actin/cofilin/myosin-dependent mechanism. J. Biol. Chem. 2009, 284:8329-8336.
62. Gu Z., et al. Activation of dopamine D4 receptors induces synaptic translocation of Ca2+/calmodulin-dependent protein kinase II in cultured prefrontal cortical neurons. Mol. Pharmacol. 2006, 69:813-822.
63. Gupta D.S., et al. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005, 57:123-131.
64. Hahn C.G., et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 2006, 12:824-828.
65. Hamshere M.L., et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the schizophrenia PGC. Mol. Psychiatry 2012, (2012 May 22 [Epub ahead of print]). 10.1038/mp.2012.67.
66. Hashimoto T., et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 2003, 23:6315-6326.
67. Hashimoto T., et al. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol. Psychiatry 2008, 13:147-161.
68. Hayashi-Takagi A., Sawa A. Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. Brain Res. Bull. 2010, 83:140-146.
69. Hayashi-Takagi A., et al. Disrupted-in-schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1. Nat. Neurosci. 2010, 13:327-332.
70. Hikida T., et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14501-14506.
71. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 2007, 27:11496-11500.
72. Honea R., et al. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 2005, 162:2233-2245.
73. Horvath S., et al. Analyzing schizophrenia by DNA microarrays. Biol. Psychiatry 2011, 69:157-162.
74. Iizuka Y., et al. Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J. Neurosci. 2007, 27:12390-12395.
75. Jaaro-Peled H., et al. Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1-ErbB4 and DISC1. Trends Neurosci. 2009, 32:485-495.
76. Jay T.M., Witter M.P. Distribution of hippocampal CA1 and subicular efferents in the prefrontal cortex of the rat studied by means of anterograde transport of Phaseolus vulgaris-leucoagglutinin. J. Comp. Neurol. 1991, 313:574-586.
77. Ji Y., et al. Role of dysbindin in dopamine receptor trafficking and cortical GABA function. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19593-19598.
78. Kamiya A. Animal models for schizophrenia via in utero gene transfer: understanding roles for genetic susceptibility factors in brain development. Prog. Brain Res. 2009, 179:9-15.
79. Kantrowitz J.T., Javitt D.C. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res. Bull. 2010, 83:108-121.
80. Karlsgodt K.H., et al. Reduced dysbindin expression mediates N-methyl-d-aspartate receptor hypofunction and impaired working memory performance. Biol. Psychiatry 2011, 69:28-34.
81. Kato T., et al. Phenotypic characterization of transgenic mice overexpressing neuregulin-1. PLoS One 2010, 5:e14185.
82. Kato T., et al. Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Mol. Psychiatry 2011, 16:307-320.
83. Katz Y., et al. Synapse distribution suggests a two-stage model of dendritic integration in CA1 pyramidal neurons. Neuron 2009, 63:171-177.
84. Kawaguchi Y., Kubota Y. Neurochemical features and synaptic connections of large physiologically-identified GABAergic cells in the rat frontal cortex. Neuroscience 1998, 85:677-701.
85. Kegeles L.S., et al. Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography. Biol. Psychiatry 2010, 68:634-641.
86. Keilhoff G., et al. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience 2004, 126:591-598.
87. Kirkpatrick B., et al. DISC1 immunoreactivity at the light and ultrastructural level in the human neocortex. J. Comp. Neurol. 2006, 497:436-450.
88. Klausberger T., et al. Cell type- and input-specific differences in the number and subtypes of synaptic GABA(A) receptors in the hippocampus. J. Neurosci. 2002, 22:2513-2521.
89. Knable M.B., et al. Molecular abnormalities in the major psychiatric illnesses: classification and regression tree (CRT) analysis of post-mortem prefrontal markers. Mol. Psychiatry 2002, 7:392-404.
90. Kolluri N., et al. Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am. J. Psychiatry 2005, 162:1200-1202.
91. Konrad A., et al. ErbB4 genotype predicts left frontotemporal structural connectivity in human brain. Neuropsychopharmacology 2009, 34:641-650.
92. Kopec C.D., et al. Glutamate receptor exocytosis and spine enlargement during chemically induced long-term potentiation. J. Neurosci. 2006, 26:2000-2009.
93. Kristiansen L.V., et al. Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia. Schizophr. Res. 2010, 119:198-209.
94. Kristiansen L.V., et al. Expression of the NR2B-NMDA receptor subunit and its Tbr-1/CINAP regulatory proteins in postmortem brain suggest altered receptor processing in schizophrenia. Synapse 2010, 64:495-502.
95. Krivosheya D., et al. ErbB4-neuregulin signaling modulates synapse development and dendritic arborization through distinct mechanisms. J. Biol. Chem. 2008, 283:32944-32956.
96. Kubo K., et al. Migration defects by DISC1 knockdown in C57BL/6, 129X1/SvJ, and ICR strains via in utero gene transfer and virus-mediated RNAi. Biochem. Biophys. Res. Commun. 2010, 400:631-637.
97. Lahti R.A., et al. Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study. Mol. Psychiatry 1998, 3:528-533.
98. Law A.J., et al. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6747-6752.
99. Law A.J., et al. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum. Mol. Genet. 2007, 16:129-141.
100. Lee K.H., et al. Synchronous gamma activity: a review and contribution to an integrative neuroscience model of schizophrenia. Brain Res. Brain Res. Rev. 2003, 41:57-78.
101. Lee F.H., et al. Disc1 point mutations in mice affect development of the cerebral cortex. J. Neurosci. 2011, 31:3197-3206.
102. Lei G., et al. Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-d-aspartate receptor-mediated synaptic strength. J. Neurochem. 2009, 109:1017-1030.
103. Lewis D.A., et al. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6:312-324.
104. Lewis D.A., et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 2008, 165:1585-1593.
105. Lewis D.A., et al. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012, 35:57-67.
106. Li H., et al. Neuregulin repellent signaling via ErbB4 restricts GABAergic interneurons to migratory paths from ganglionic eminence to cortical destinations. Neural Dev. 2012, 7:10.
107. Li Y., et al. Less efficient information transfer in Cys-allele carriers of DISC1: a brain network study based on diffusion MRI. Cereb. Cortex 2012, (first published online June 12, 2012). 10.1093/cercor/bhs167.
108. Marenco S., et al. Genetic association of ErbB4 and human cortical GABA levels in vivo. J. Neurosci. 2011, 31:11628-11632.
109. Mathalon D.H., et al. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch. Gen. Psychiatry 2001, 58:148-157.
110. Matsuzaki M., et al. Structural basis of long-term potentiation in single dendritic spines. Nature 2004, 429:761-766.
111. Mead C.L., et al. Cytosolic protein interactions of the schizophrenia susceptibility gene dysbindin. J. Neurochem. 2010, 113(6):1491-1503.
112. Mei L., Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008, 9:437-452.
113. Mirnics K., et al. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28:53-67.
114. Mrzljak L., et al. Localization of dopamine D4 receptors in GABAergic neurons of the primate brain. Nature 1996, 381:245-248.
115. Mullin A.P., et al. Cell biology of the BLOC-1 complex subunit dysbindin, a schizophrenia susceptibility gene. Mol. Neurobiol. 2011, 44:53-64.
116. Murotani T., et al. High dopamine turnover in the brains of Sandy mice. Neurosci. Lett. 2007, 421:47-51.
117. Murray A.M., et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J. Neurosci. 1995, 15:2186-2191.
118. Murray A.J., et al. Parvalbumin-positive CA1 interneurons are required for spatial working but not for reference memory. Nat. Neurosci. 2011, 14:297-299.
119. Nagai T., et al. Dysfunction of dopamine release in the prefrontal cortex of dysbindin deficient sandy mice: an in vivo microdialysis study. Neurosci. Lett. 2010, 470:134-138.
120. Negyessy L., Goldman-Rakic P.S. Subcellular localization of the dopamine D2 receptor and coexistence with the calcium-binding protein neuronal calcium sensor-1 in the primate prefrontal cortex. J. Comp. Neurol. 2005, 488:464-475.
121. Nickl-Jockschat T., et al. The impact of a Dysbindin schizophrenia susceptibility variant on fiber tract integrity in healthy individuals: a TBSS-based diffusion tensor imaging study. NeuroImage 2012, 60:847-853.
122. Niwa M., et al. Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron 2010, 65:480-489.
123. O'Donnell P. Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models. Schizophr. Bull. 2011, 37:484-492.
124. Okubo Y., et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997, 385:634-636.
125. O'Rourke N.A., et al. Deep molecular diversity of mammalian synapses: why it matters and how to measure it. Nat. Rev. Neurosci. 2012, 13:365-379.
126. Ottis P., et al. Convergence of two independent mental disease genes on the protein level: recruitment of dysbindin to cell-invasive disrupted-in-schizophrenia 1 aggresomes. Biol. Psychiatry 2011, 70:604-610.
127. Papaleo F., et al. Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. Mol. Psychiatry 2012, 17:85-98.
128. Paspalas C.D., Goldman-Rakic P.S. Presynaptic D1 dopamine receptors in primate prefrontal cortex: target-specific expression in the glutamatergic synapse. J. Neurosci. 2005, 25:1260-1267.
129. Paspalas C.D., et al. Constellation of HCN channels and cAMP regulating proteins in dendritic spines of the primate prefrontal cortex: potential substrate for working memory deficits in schizophrenia. Cereb. Cortex 2012, (First published online: June 12, 2012). 10.1093/cercor/bhs152.
130. Peel A.L., et al. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 1997, 4:16-24.
131. Phillips O.R., et al. Mapping corticocortical structural integrity in schizophrenia and effects of genetic liability. Biol. Psychiatry 2011, 70:680-689.
132. Plantje J.F., et al. D2-dopamine receptors regulate the release of [3H]dopamine in rat basal hypothalamus and neurointermediate lobe of the pituitary gland. Brain Res. 1987, 413:205-212.
133. Pletnikov M.V. Inducible and conditional transgenic mouse models of schizophrenia. Prog. Brain Res. 2009, 179:35-47.
134. Polsky A., et al. Computational subunits in thin dendrites of pyramidal cells. Nat. Neurosci. 2004, 7:621-627.
135. Retaux S., et al. Opposing effects of dopamine D2 receptor stimulation on the spontaneous and the electrically evoked release of [3H]GABA on rat prefrontal cortex slices. Neuroscience 1991, 42:61-71.
136. Rico B., Marin O. Neuregulin signaling, cortical circuitry development and schizophrenia. Curr. Opin. Genet. Dev. 2011, 21:262-270.
137. Ripke S., et al. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976.
138. Rivera A., et al. Cellular localization and distribution of dopamine D(4) receptors in the rat cerebral cortex and their relationship with the cortical dopaminergic and noradrenergic nerve terminal networks. Neuroscience 2008, 155:997-1010.
139. Romon T., et al. Expression of parvalbumin and glutamic acid decarboxylase-67 after acute administration of MK-801. Implications for the NMDA hypofunction model of schizophrenia. Psychopharmacology (Berl) 2011, 217:231-238.
140. Rotaru D.C., et al. The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia. Rev. Neurosci. 2012, 23:97-109.
141. Sawa A. Preface. This volume focuses on how genetic models for schizophrenia, that is, manipulation in genetic susceptibility factors for the disease, have potential in opening a new window of better understanding of etiology-relevant mechanisms. Prog. Brain Res. 2009, 179:vii.
142. Sawaguchi T., Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991, 251:947-950.
143. Seamans J.K., Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 2004, 74:1-58.
144. Seamans J.K., et al. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J. Neurosci. 2001, 21:3628-3638.
145. Seeman P., et al. Dopamine D4 receptors elevated in schizophrenia. Nature 1993, 365:441-445.
146. Selemon L.D., Goldman-Rakic P.S. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol. Psychiatry 1999, 45:17-25.
147. Seshadri A.J., Hayashi-Takagi A. Gene manipulation with stereotaxic viral infection for psychiatric research: spatiotemporal components for schizophrenia. Prog. Brain Res. 2009, 179:17-27.
148. Seshadri S., et al. Disrupted-in-schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5622-5627.
149. Shen S., et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J. Neurosci. 2008, 28:10893-10904.
150. Silberberg G., et al. The involvement of ErbB4 with schizophrenia: association and expression studies. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B:142-148.
151. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J. Neurochem. 1998, 71:2454-2464.
152. Sorra K.E., Harris K.M. Overview on the structure, composition, function, development, and plasticity of hippocampal dendritic spines. Hippocampus 2000, 10:501-511.
153. Spruston N. Pyramidal neurons: dendritic structure and synaptic integration. Nat. Rev. Neurosci. 2008, 9:206-221.
154. Stefani M.R., Moghaddam B. Transient N-methyl-d-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol. Psychiatry 2005, 57:433-436.
155. Steinecke A., et al. Disrupted-in-schizophrenia 1 (DISC1) is necessary for the correct migration of cortical interneurons. J. Neurosci. 2012, 32:738-745.
156. Suhara T., et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch. Gen. Psychiatry 2002, 59:25-30.
157. Tang J., et al. Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum. Mol. Genet. 2009, 18:3851-3863.
158. Ting A.K., et al. Neuregulin 1 promotes excitatory synapse development and function in GABAergic interneurons. J. Neurosci. 2011, 31:15-25.
159. Tseng K.Y., O'Donnell P. Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J. Neurosci. 2004, 24:5131-5139.
160. Tseng K.Y., et al. Post-pubertal disruption of medial prefrontal cortical dopamine-glutamate interactions in a developmental animal model of schizophrenia. Biol. Psychiatry 2007, 62:730-738.
161. Tuppurainen H., et al. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol. Psychiatry 2003, 8:453-455.
162. Volk D., et al. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am. J. Psychiatry 2001, 158:256-265.
163. Volk D.W., et al. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb. Cortex 2002, 12:1063-1070.
164. Vullhorst D., et al. Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. J. Neurosci. 2009, 29:12255-12264.
165. Wang Q., Charych E.I., Pulito V.L., Lee J.B., Graziane N.M., Crozier R.A., Revilla-Sanchez R., Kelly M.P., Dunlop A.J., Murdoch H., Taylor N., Xie Y., Pausch M., Hayashi-Takagi A., Ishizuka K., Seshadri S., Bates B., Kariya K., Sawa A., Weinberg R.J., Moss S.J., Houslay M.D., Yan Z., Brandon N.J. The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function. Mol. Psychiatry 2011, 16(10):1006-1023. (Oct) (Epub 2010 Sep 14). 10.1038/mp.2010.87.
166. Wen L., et al. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1211-1216.
167. Williams H.J., et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol. Psychiatry 2011, 16:429-441.
168. Winterer G., et al. Association of 5' end neuregulin-1 (NRG1) gene variation with subcortical medial frontal microstructure in humans. NeuroImage 2008, 40:712-718.
169. Wong D.F., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986, 234:1558-1563.
170. Woo T.U., et al. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5341-5346.
171. Ye T., et al. Analysis of copy number variations in brain DNA from patients with schizophrenia and other psychiatric disorders. Biol. Psychiatry 2012, 72:651-654.
172. Yoon J.H., et al. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J. Neurosci. 2010, 30:3777-3781.
173. Yozu M., et al. The caudal migratory stream: a novel migratory stream of interneurons derived from the caudal ganglionic eminence in the developing mouse forebrain. J. Neurosci. 2005, 25:7268-7277.
174. Yuen E.Y., Yan Z. Dopamine D4 receptors regulate AMPA receptor trafficking and glutamatergic transmission in GABAergic interneurons of prefrontal cortex. J. Neurosci. 2009, 29:550-562.
175. Zeng H., et al. Large-scale cellular-resolution gene profiling in human neocortex reveals species-specific molecular signatures. Cell 2012, 149:483-496.
176. Zhang Z., Sun Q.Q. Development of NMDA NR2 subunits and their roles in critical period maturation of neocortical GABAergic interneurons. Dev. Neurobiol. 2011, 71:221-245.
177. Zhang L., et al. Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. J. Neurochem. 2004, 91:1358-1368.